Karuppasamy Manikandan, van Rooyen Jason
eBIC-for-Industry, Diamond Light Source, Harwell Science and Innovation Campus, Didcot OX11 0DE, United Kingdom.
Acta Crystallogr F Struct Biol Commun. 2025 Mar 1;81(Pt 3):118-122. doi: 10.1107/S2053230X25001098. Epub 2025 Feb 20.
The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR) regulates the level of cholesterol by catalysing the formation/production of mevalonate and has therefore become an important pharmaceutical target for coronary heart disease. Here, we report the cryo-EM structure of the catalytic part of the enzyme in the apo form and bound with its inhibitor atorvastatin, a commonly used drug in cardiovascular disease, at resolutions of 2.1 and 2.3 Å, respectively. In the cryo-EM maps, part of the N-domain corresponding to amino acids 439-487 is well ordered and could be modelled completely. Atorvastatin molecules were found to occupy all four active sites of the tetrameric complex, and the binding does not alter the conformation of the protein or the active site. The method described here exploits graphene oxide as an additional support and could be used as an alternative to elucidate the structures of pharmaceutical target compounds that are difficult to co-crystallize with human HMGR and for sparsely available samples in drug discovery.
3-羟基-3-甲基戊二酰辅酶A还原酶(HMGR)通过催化甲羟戊酸的形成/产生来调节胆固醇水平,因此已成为冠心病的重要药物靶点。在此,我们分别以2.1 Å和2.3 Å的分辨率报告了该酶无apo形式及其与常用心血管疾病药物阿托伐他汀结合的催化部分的冷冻电镜结构。在冷冻电镜图谱中,对应于氨基酸439-487的N结构域的一部分排列良好,可以完全建模。发现阿托伐他汀分子占据四聚体复合物的所有四个活性位点,并且结合不会改变蛋白质的构象或活性位点。这里描述的方法利用氧化石墨烯作为额外的支持物,可作为一种替代方法来阐明难以与人HMGR共结晶的药物靶标化合物的结构以及药物发现中稀少可用的样品。